NCT04009577 - A Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant (LEM) for the Treatment of Insomnia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 15, 2019

Primary Completion Date

March 17, 2020

Study Completion Date

June 26, 2020

Conditions

Insomnia

Interventions

DRUG

LEM 5 mg

LEM tablet.

DRUG

LEM 10 mg

LEM tablet.

Trial Locations (17)

10019

Clinilabs Drug Development Corporation, New York

21075

Centennial Medical Group - Elkridge - Rx Trials, Elkridge

30281

SleepCare Research Institute Inc, Stockbridge

30342

NeuroTrials Research Inc. - BTC - PPDS, Atlanta

32003

Fleming Island Center For Clinical Research - ERN-PPDS, Fleming Island

32256

Clinical Neuroscience Solutions Inc, Jacksonville

32801

Clinical Neuroscience Solutions Inc, Orlando

33009

MD Clinical, Hallandale

38119

Clinical Neuroscience Solutions Inc, Memphis

45212

CTI Clinical Research Center - ClinEdge - PPDS, Cincinnati

60634

Chicago Research Center Inc - ClinEdge - PPDS, Chicago

78731

FutureSearch Trials of Neurology, Austin

85306

PACT, Glendale

87109

Albuquerque Neurosciences Inc, Albuquerque

92103

Artemis Institute For Clinical Research LLC - San Diego - ClinEdge - PPDS, San Diego

92705

SDS Clinical Trials, Inc., Santa Ana

95821

Northern California Research Corp, Sacramento

All Listed Sponsors

lead

Eisai Inc.

INDUSTRY